Comparative – Research


ResearchModels for developing medical devices for treating vascular disease – Innovate UK – KTP and The Whiteley Clinic – 2015- 2018

The project aims to bring a new mechanical device to market in three years that will drastically reduce recovery times and future recurrences of what are common conditions affecting millions.

Our three-year KTP with The Whiteley Clinic (headquartered at the Surrey Research Park) aims to develop a new medical device to treat truncal and pelvic varicose veins. The Clinic will benefit from knowledge and expertise from the School of Veterinary Medicine, the Centre of Biomedical Engineering and Surrey Business School. This KTP has the potential to advance venous surgery on a worldwide scale, leading to improved patient care.


Novel Antimicrobial Agents for Bacterial Pathogens of Livestock – BBSRC – 2015-2018.

Antimicrobial resistance is a growing problem in the UK and worldwide. We urgently need ways to counteract the effects of the antimicrobial resistance of bacteria in human and animal health. One promising approach is through novel alternatives or additions to antibiotics, so that antibiotics are used less, resistance is countered, and costs are lowered. Carbon monoxide (CO) is a colourless and odourless gas, and an infamous respiratory poison, notorious as the ‘silent killer’ originating from domestic gas appliances, motor car exhausts and various industrial processes. However, it is also known to be a vital small signaling molecule (or ‘gasotransmitter’) in microbes, animals and plants. We still know relatively little about how CO gas exerts its many important effects in inflammation, the cardiovascular system and elsewhere. One reason for this is that it is difficult to deliver and manipulate CO doses in biological systems. When CO is applied by inhalation, as is currently being explored in medicine, the final distribution of the gas is difficult to tune, while application to localised sites, e.g. of microbial infection, is virtually impossible. However, because, in small doses, CO has beneficial and essential roles in biology, researchers have started in the last 10 years to evaluate CO-releasing molecules (CORMs) as easy-to-handle, safer and more selective ways to administer CO. Remarkably, these compounds can kill bacteria and the way they work appears entirely different from currently prescribed antibiotics. This proposal focuses on the antimicrobial applications of CORMs in which CO release is triggered on demand by light (PhotoCORMs) so that we can deliver the gas selectively to sites of microbial infection and at chosen times. We aim to understand the antibacterial effects of CORMS in general, and PhotoCORMs in particular, in comparison with more established antimicrobial compounds.


Novel strategies to Detect & Prevent the emergency of AMR in zoonotic Pathogens

Antimicrobial resistance (AMR) is one of the most critical challenges facing science in the 21st century. For decades we have benefited from the widespread availability of drugs to treat a variety of conditions using antibiotics with penicillin becoming one of the most recognizable drugs in terms of public awareness. However, through the natural evolution of pathogens, accelerated by the over-use of antimicrobial drugs, the effectiveness of current treatments to such interventions is reducing. Indeed the emergence of pathogens which are fully resistant to antimicrobial drugs, though limited, is becoming an increasing trend. As a direct result of the serious implications and threats this poses the UK has established a 5-year AMR challenge to researchers, mirrored internationally, to address these issues. In considering AMR it is important that the risk to human health from the emergence of AMR in livestock is also recognized and addressed. The use of antibiotics in this context is also widespread, and the emergence of AMR is occurring as seen in human pathogens. Given the food chain, and environmental factors such as waste treatment and run-off, there is significant risk that this may offer a pathway for the translation of AMR pathogens from animals into humans.

The Comparative Pathology CAG has successfully been awarded the following:

  • Models for developing medical devices for treating vascular disease

Research Council: BBSRC KTP

Award size: £350,000

  • Novel Antimicrobial Agents for Bacterial Pathogens of Livestock

Research Council: BBSRC

Award size: £328,447

  • Novel strategies to Detect & Prevent the emergency of AMR in zoonotic Pathagens

Research Council: EPSRC

Award size: £461,852


Our CAG also applied but was unsuccessful for the following award:

  • Development of pen-side tests for zoonotic pathogens

Research Council: Commercially funded

Award amount: £40,000

©2018 Surrey Health Partners

Log in with your credentials

Forgot your details?